1 November 2017

Board changes

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Group"), the global pharmaceutical and services company, announces a number of Board changes.

Chris Rigg today joins as an executive director with immediate effect, having previously served as Chief Executive of Quantum Pharma Plc ("Quantum"). Anne Hyland joins as a non-executive director with effect from 1 January 2018, whilst non-executive directors, Peter George and John Bacon, are stepping down with immediate effect.

Chris Rigg was appointed as CEO of Quantum in October 2016 having previously served as Quantum's CFO and Strategy Director. Prior to Quantum, Chris was CEO of NRG, a national recruitment agency and prior to that he was head of Barclays Bank's North East large corporate banking division.  Previously, he worked at EAGA plc, the UK support services group, and in corporate finance with Deloitte. He qualified as a chartered accountant with PwC. 

Anne is CFO of Kymab Ltd, a private biopharmaceutical company. She is also a non-executive director of Elementis plc, a global specialty chemicals company. Previously, she was CFO of BBI Diagnostics Group Ltd and FTSE-listed Vectura Group plc. Prior to her role at Vectura, Anne held a number of senior finance positions at Celltech Group plc, Medeva plc and KPMG. She is a qualified chartered accountant (FCA), and corporate tax adviser (CTA - AITI).

Anne will become chair of the Audit and Risk Committee.

Peter Allen, Chairman said:

"We are delighted to welcome Chris and Anne. Chris has extensive relevant experience from his executive roles; Anne has significant experience from both her executive and her non-executive positions.

"On behalf of everyone at Clinigen, I want to thank Peter. As we said last year when he stepped down as CEO, Peter has done a tremendous job developing and growing Clinigen. Since then, as a non-executive director, he has been a major support to the Board.   

"Also, I'd like to thank John. He has made a valuable contribution following the acquisition of Link, through his expertise in the Africa and Asia Pacific markets. 

"We wish both Peter and John well."

The following information is disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies

Christian ("Chris") Alexander Rigg, aged 43, is currently or has been a director of the following companies during the five years preceding the date of this announcement:

Mr Rigg is also a director of NuPharm Laboratories Limited which is currently going through an administration process.

Chris is entitled to receive, and is expected to hold upon admission, 6,563 ordinary shares of 0.1p each in Clinigen as a result of the scheme of arrangement with Quantum Pharma Plc having become effective earlier today.

Anne Philomena Hyland, aged 57, is currently or has been a director of the following companies during the five years preceding the date of this announcement:

There is no further information to be disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

- Ends -

Contact Details

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com